Now that the Dust Has Settled: Billing & Coding in 2023

Now That The Dust Has Settled: Billing & Coding in 2023

Are you interested in learning what changes are currently taking affect in billing and coding for 2023?  Then join us for this one hour webinar that will address these changes so you know how to move forward in 2023. To learn more or to register for this event, click the link below. 

more information

Oncology Certified Nursing (OCN) Review Course

Oncology Certified Nursing (OCN) Review Course

Calling all RN's who would like to get certified in oncology nursing. Now is your opportunity!  MSHO is hosting the OCN Review Course this March for those seeking to get certified or desire a refresher course. To learn more or to register for this event, click the link below. 

more information

MSHO & WPS Outpatient Hospital Reimbursement

MSHO & WPS Outpatient Hospital Reimbursement

Do you have questions about outpatient hospital billing or medical oncology services? Look no further and join us for a one hour webinar where your questions can be answered. To learn more or to register for this event, click the link below. 

more information

MSHO Precision Medicine Symposium

MSHO Precision Medicine Symposium

Join us for this first of a kind symposium designed to discuss current standards of genomic assessment for the management of patients with specific tumors.  To learn more or to register for this event, click the link below. 

more information

Cervical Cancer Awareness Month

Cervical Cancer Awareness Month

More than 14,000 women in the United States are diagnosed with invasive cervical cancer each year, but the disease is preventable with vaccination and appropriate screening.

more information

Healthcare Bill Tracking

Track Healthcare Legislation Happening in Michigan!

Updated October 10, 2022

Follow legislation that MSHO is actively monitoring that may impact you and your patients. 

more information

NCCN Guidelines Updates

NCCN Guidelines Updates

January 31, 2023

NCCN Guidelines Updated for Antiemesis.

more information

Previous Next

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

January is National Blood Donor Month!

Schedule your next donation today and be a part of the campaign to spread awareness of the need for blood.

Upcoming Events view all events

 January 2023 
SMTWTFS
1234567
891011121314
15161718192021
222324
25
26
2728
293031    
Wed
1
2023
February 1, 2023

Now that the Dust has Settled: Billing & Coding in 2023

12:00PM - 1:00PM

Webinar

view event details
Mon
6
2023
March 6, 2023

Oncology Certified Nurse (OCN) Review Course

MSU Management Education Center, Troy MI

view event details
Mon
6
2023
March 6-7, 2023

Certified Hematology & Oncology Coder (CHONC) Review Course

MSU Management Education Center, Troy MI

view event details

Latest News view all news

FDA Approves Lilly's Jaypirca™ (pirtobrutinib), the 1st & Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
01/31/2023

FDA Approves Lilly's Jaypirca™ (pirtobrutinib), the 1st & Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA NSCLC
01/27/2023

FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA NSCLC

2023 Ambulatory Surgical Center Fee Schedules Released
01/20/2023

2023 Ambulatory Surgical Center Fee Schedules Released

2023 Medicare Physician Fee Schedules Released
01/20/2023

2023 Medicare Physician Fee Schedules Released

Follow Us on Twitter

Corporate Sponsors view all sponsors